![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
GSK PLC 19 July 2024 Issued: 19 July 2024, London UK Blenrep (belantamab mafodotin) combinations in multiple myeloma application accepted for review by the European Medicines Agency ●...
GSK PLC on Friday said its treatment for relapsed or refractory multiple myeloma has been accepted for review by a Eu ...
GSK PLC 18 July 2024 GSK plc (the 'Company') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Emma Walmsley b) Position/status Chief Executive...
GSK PLC 16 July 2024 GSK plc (the 'Company') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Emma Walmsley b) Position/status Chief Executive...
GSK PLC 15 July 2024 GSK plc (the 'Company') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Emma Walmsley b) Position/status Chief...
Pharmaceutical company GSK PLC is set to move its global headquarters back to central London, ending more than two de ...
GSK PLC 12 July 2024 GSK plc (the 'Company') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Emma Walmsley b) Position/status Chief Executive...
The ongoing Zantac overhang plus reduced forecasts for Arexvy and Shingrix contributed to UBS lowering its investment ...
GSK PLC on Wednesday restructured an existing collaboration with CureVac NV into a new licensing agreement to take co ...
GSK PLC 03 July 2024 Issued: 3 July 2024, London UK; Tübingen, Germany/ Boston, MA, USA GSK and CureVac to restructure collaboration into new licensing agreement · GSK acquires full...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 16 | 1.06065628107 | 1508.5 | 1549 | 1485.5 | 5218468 | 1516.58785983 | DE |
4 | -77 | -4.80799250702 | 1601.5 | 1616.5 | 1484 | 7282997 | 1534.64113041 | DE |
12 | -125.5 | -7.60606060606 | 1650 | 1820 | 1484 | 7721674 | 1640.6592399 | DE |
26 | -38.3 | -2.45072945994 | 1562.8 | 1820 | 1484 | 7995025 | 1641.61858181 | DE |
52 | 135.7 | 9.77102534562 | 1388.8 | 1820 | 1330.2 | 7510726 | 1553.88022409 | DE |
156 | 112.7 | 7.98271709874 | 1411.8 | 1824.4 | 1283.2 | 8597251 | 1529.34209563 | DE |
260 | -121.9 | -7.40403304179 | 1646.4 | 1857 | 1190.8 | 8882499 | 1526.2962026 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions